UBS Group’s AbCellera Biologics ABCL Stock Holding History

UBS Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57M	Buy	+200,000	New	+$978K	﹤0.01%	5328

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

UBS Group's ABCL Position: Q2 2026 in Review

UBS Group reduced its AbCellera Biologics (ABCL) stake by 56% in Q2 2026, selling an estimated $11.4M and leaving 1,870,633 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3010.

UBS Group first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $14.7M in Q1 2026. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

UBS Group held 1,870,633 shares of AbCellera Biologics worth $14.7M as of Q2 2026.
UBS Group sold 2,338,419 AbCellera Biologics shares in Q2 2026, an estimated $11.4M.
AbCellera Biologics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3010 holding.
UBS Group first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
UBS Group's AbCellera Biologics position peaked at $14.7M in Q1 2026.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.